|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Myonexus_Therapeutics
|
|
gptkbp:annual_report
|
Sarepta Therapeutics Annual Report 2020
|
|
gptkbp:ceo
|
gptkb:Doug_Ingram
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:United_States
gptkb:Duchenne_muscular_dystrophy
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaboration
|
gptkb:Duke_University
gptkb:Harvard_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Michigan
gptkb:University_of_Pennsylvania
gptkb:University_of_Washington
gptkb:National_Institutes_of_Health
gptkb:University_of_California,_San_Diego
gptkb:University_of_Southern_California
gptkb:University_of_Florida
gptkb:Children's_Hospital_of_Philadelphia
|
|
gptkbp:fda_approval
|
gptkb:Viltolarsen
gptkb:Eteplirsen
gptkb:Golodirsen
gptkb:Casimersen
|
|
gptkbp:focus
|
genetic medicine
|
|
gptkbp:founded
|
gptkb:1980
|
|
gptkbp:founder
|
gptkb:Chris_Garabedian
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sarepta Therapeutics
|
|
gptkbp:instruction_set
|
Gene therapy products
Duchenne muscular dystrophy treatments
Exon skipping therapies
|
|
gptkbp:investment
|
Sarepta Therapeutics Investor Relations
|
|
gptkbp:leadership
|
gptkb:CEO
gptkb:Board_of_Directors
|
|
gptkbp:mission
|
transform the lives of patients with rare diseases.
|
|
gptkbp:notable_products
|
gptkb:Viltolarsen
gptkb:Eteplirsen
gptkb:Golodirsen
gptkb:Casimersen
|
|
gptkbp:number_of_employees
|
over 300
|
|
gptkbp:partnership
|
gptkb:Genentech
gptkb:Pfizer
|
|
gptkbp:publicly_traded
|
gptkb:NASDAQ
|
|
gptkbp:research_areas
|
rare diseases
neuromuscular diseases
muscle diseases
|
|
gptkbp:revenue
|
$100 million (2020)
|
|
gptkbp:stock_symbol
|
SRPT
|
|
gptkbp:vision
|
be a leader in genetic medicine.
|
|
gptkbp:website
|
www.sareptatherapeutics.com
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
4
|